Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard P Baum

Showing results (21-30 of 198) with videos related to

Pageof 20
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2018
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive StrategiesThomas Langbein, Guillaume Chaussé, Richard P Baum
Seminars in Nuclear Medicine|August 25, 2016
Advances in the Diagnosis of Neuroendocrine NeoplasmsHarshad R Kulkarni, Aviral Singh, Richard P Baum
Clinical Nuclear Medicine|November 13, 2019
Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT ImagingJingjing Zhang, Harshad R Kulkarni, Richard P Baum
Seminars in Nuclear Medicine|April 6, 2012
Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasmsRichard P Baum, Harshad R Kulkarni, Cecilia Carreras
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patientHarshad R Kulkarni, Christiane Schuchardt, Richard P Baum
Frontiers in Medicine|October 24, 2024
Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case reportCarsten S Kramer, Jingjing Zhang, Richard P Baum
PET Clinics|March 8, 2017
Imaging of Prostate Cancer Using <sup>64</sup>Cu-Labeled Prostate-Specific Membrane Antigen LigandAviral Singh, Harshad R Kulkarni, Richard P Baum
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumorsCecilia Carreras, Harshad R Kulkarni, Richard P Baum
Annals of Translational Medicine|October 22, 2014
THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasmsDieter Hörsch, Harshad R Kulkarni, Richard P Baum
Clinical Nuclear Medicine|January 25, 2020
Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide TherapyJingjing Zhang, Harshad R Kulkarni, Richard P Baum
Pageof 20

Showing results (21-30 of 198) with videos related to

Sort By:
Pageof 20
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2018
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive StrategiesThomas Langbein, Guillaume Chaussé, Richard P Baum
Seminars in Nuclear Medicine|August 25, 2016
Advances in the Diagnosis of Neuroendocrine NeoplasmsHarshad R Kulkarni, Aviral Singh, Richard P Baum
Clinical Nuclear Medicine|November 13, 2019
Ectopic Corticotropin-Releasing Hormone-Secreting Pancreatic Neuroendocrine Tumor: Excellent Response of Liver Metastases to Peptide Receptor Radionuclide Therapy as Demonstrated by 68Ga-DOTATOC and 18F-FDG PET/CT ImagingJingjing Zhang, Harshad R Kulkarni, Richard P Baum
Seminars in Nuclear Medicine|April 6, 2012
Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasmsRichard P Baum, Harshad R Kulkarni, Cecilia Carreras
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patientHarshad R Kulkarni, Christiane Schuchardt, Richard P Baum
Frontiers in Medicine|October 24, 2024
Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case reportCarsten S Kramer, Jingjing Zhang, Richard P Baum
PET Clinics|March 8, 2017
Imaging of Prostate Cancer Using <sup>64</sup>Cu-Labeled Prostate-Specific Membrane Antigen LigandAviral Singh, Harshad R Kulkarni, Richard P Baum
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumorsCecilia Carreras, Harshad R Kulkarni, Richard P Baum
Annals of Translational Medicine|October 22, 2014
THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasmsDieter Hörsch, Harshad R Kulkarni, Richard P Baum
Clinical Nuclear Medicine|January 25, 2020
Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide TherapyJingjing Zhang, Harshad R Kulkarni, Richard P Baum
Pageof 20